SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Introgen Therapeutics
An SI Board Since February 2004
Posts SubjectMarks Bans Symbol
802 21 0 INGN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
202BIO Investor Conference Zeros in on Major Health Issues Monday January 31, 3:28 zeta19612/11/2005
201bio.com <i>Fisher quoted about PEG 3..no mention of p53 and mda7 althoughzeta19611/25/2005
200Is There Still a Role for Induction Chemotherapy for Head and Neck Cancer? Adamzeta19611/24/2005
199Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapyzeta19611/24/2005
198leaddiscovery.co.uk A report on INGN's and other companies' oncolytic pzeta19611/20/2005
197ON THE EVE OF MEDICAL HISTORY Experts say gene therapy had learned its lessons-zeta19611/17/2005
196<<H&N cancer results or sumthin?>> right on!..sumthin!..a pizzazeta19611/14/2005
195Yeah, I found that, it's one of the links at the bottom here: Message 20942tuck1/14/2005
194peg-3 followup: I didn't read the link in last msg very carefully. Looks lfred hayes1/14/2005
193who owns peg-3?: Columbia University filed patent application July 20, 2000, bufred hayes1/14/2005
192>>I would imagine that in order for PEG3 to be utilized commercially for ptuck1/13/2005
191Good point tuck, but I would imagine that in order for PEG3 to be utilized commezeta19611/13/2005
190Zeta and I both know INGN owns gene therapy applications of MDA-7 three ways frotuck1/12/2005
189Zeta, FWIW ("when that occurred"): AUSTIN, TX - Aug. 4, 1999 - Introgefred hayes1/12/2005
188<I> Note the authors and keywords. Do we have an INGN connection of substaJibacoa1/12/2005
187On first blush, it looks like it should involve INGN..the third link mentions uszeta19611/12/2005
186[Targeting gene expression selectively in cancer cells using the PEG-3 promoter]tuck1/12/2005
185FWIW, INGN is one of the surprisingly few biotechs on the Reg. SHO threshold sectuck1/10/2005
184FWIW, INGN is one of the surprisingly few biotechs on the Reg. SHO threshold sectuck1/10/2005
183For those interested, more mda7 publicity. Cancer Gene Ther. 2004 Dec 03; [Eputobrntob1/6/2005
182I'm afraid not - at least not without paying, that is. <g> PeterBiomaven12/31/2004
181Thanks Bernard..wow..how do you keep track? imho, medical device companies are zeta196112/31/2004
180Thanks Peter! Do you have access to the papers? Mda7 will be getting a bunch ozeta196112/31/2004
179Mol Ther. 2005 Jan;11(1):149-59. Related Articles, Links Clinical and locaBiomaven12/30/2004
178<B> O.T.</B> <i>Any '05 picks?</I> My interests arJibacoa12/29/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News